

**S2 Table.** Characteristics of patients without extracranial recurrence risk factors

Characteristics	PCI (n=32)	No PCI (n=9)	p-value
Age (yr)	62 (39-74)	70 (56-85)	0.041
Sex			0.299
Male	25 (78.1)	9 (100)	
Female	7 (21.9)	0	
Smoking history	24 (75.0)	8 (88.9)	0.665
Pack-year of smokers	40 (15-80)	55 (25-74)	0.279
FEV <sub>1</sub> (L)	2.35 (1.22-4.01)	2.21 (1.33-3.63)	0.945
FEV <sub>1</sub> /FVC (%)	71.5 (39-82)	64 (56-77)	0.537
ECOG performance status at presentation			0.493
0-1	32 (100)	8 (88.9)	
2-3	0	1 (11.1)	
Clinical T category			0.009
T1	19 (59.4)	1 (11.1)	
T2	10 (31.2)	8 (88.9)	
T3	3 (9.4)	0	
Clinical N category			> 0.99
N0	16 (50.0)	5 (55.6)	
N1	16 (50.0)	4 (44.4)	
Disease stage (AJCC 8th)			0.275
IA	8 (25.0)	1 (11.1)	
IB	3 (9.4)	3 (33.3)	
IIA	2 (6.2)	1 (11.1)	
IIB	19 (59.4)	4 (44.4)	
Chemoradiation sequence			
Concurrent	32 (100)	9 (100)	
Thoracic radiation modality			0.039
3D-CRT	31 (96.9)	6 (66.7)	
IMRT (VMAT)	1 (3.1)	3 (33.3)	
Thoracic radiation total dose (Gy)	54 (50-72)	60 (54-60)	0.377
Thoracic radiation fractionation	27 (18-33)	30 (18-31)	0.465
Chemotherapy regimen			0.049

Etoposide and cisplatin	29 (90.6)	5 (55.6)	
Etoposide and carboplatin	3 (9.4)	4 (44.4)	
PCI dose-fractionation scheme			
25 Gy/10 fx	29 (90.6)	-	
30 Gy/10 fx	3 (9.4)	-	
Response to chemoradiation (RECIST)			0.971
Complete response	6 (18.8)	1 (11.1)	
Partial response	26 (81.2)	8 (88.9)	

Values are presented as median (range) or number (%). 3D-CRT, three-dimensional conformal radiation therapy; AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; IMRT, intensity-modulated radiation therapy; PCI, prophylactic cranial irradiation; RECIST, Response Evaluation Criteria in Solid Tumors; VMAT, volumetric-modulated arc therapy.